The CHALLENGE Trial by the Canadian Cancer Trials Group (CCTG) spanned 15 years, 889 patients, and 55 sites. It provides the first robust evidence that structured exercise can significantly improve cancer survival and recurrence. Notably, the benefit from exercise delivered after surgery and adjuvant chemotherapy was similar to many current standard drug treatments.
These ground-breaking findings were presented at the 2025 annual American Society of Clinical Oncology (ASCO) meeting and published in the New England Journal of Medicine. We congratulate everyone who was involved in this trial, including many current and past members of the CEP Lab who delivered the interventions, as well as the participants.
Read here: https://www.nejm.org/doi/full/10.1056/NEJMoa2502760
Comments are closed, but trackbacks and pingbacks are open.